Clik here to view.
武田薬品、第2a相概念実証試験の良好な結果を受けて画期的新薬候補のセリアック病治療薬のライセンスをCOURより取得
大阪 & シカゴ （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502/NYSE:TAK）（以下、「武田薬品」）とCOUR Pharmaceutical Development Company,...
View ArticleClik here to view.
Usona Institute PSIL201 Study Site Now Recruiting Patients with Depression
MADISON, Wis. Usona Institute activated its first clinical trial site within NYU School of Medicine, on October 15, 2019 for a Phase 2 clinical trial (PSIL201) investigating the safety and efficacy...
View ArticleClik here to view.
持続可能な開発目標（SDGs）を支える分野横断的協業を促進すべく、グローバル・ヘルス・プログレスが発足
ジュネーブ ビジネスワイヤ） — 特にSDG17の「パートナーシップで目標を達成しよう」に重点を置いてSDGsを支えるべく、国際製薬団体連合会（IFPMA）はグローバル・ヘルス・プログレスを発足させました。このナレッジハブは、業界によるSDGsへの貢献を紹介するとともに、さらなる連携機会を拡大するためのものです。...
View ArticleClik here to view.
新推出的Global Health Progress将促进跨领域合作以支持可持续发展目标(SDG)
日内瓦 (美国商业资讯)–为支持可持续发展目标(SDG)，尤其是目标17：促进目标实现的伙伴关系，国际制药商协会联合会(IFPMA)推出Global Health Progress。这个知识中心重点介绍了制药行业对SDG做出的贡献，并为进一步的合作增加机会。...
View ArticleClik here to view.
Fresenius Medical Care Celebrates 10th Anniversary and Expansion of Their...
PERTH, Australia Fresenius Medical Care, the world’s leading provider of dialysis products and services, announced the further enhancement of support for home dialysis patients in Western Australia....
View ArticleClik here to view.
HiFiBiO Therapeutics Establishes World-Class Scientific Advisory Board
CAMBRIDGE, Mass. & SHANGHAI & PARIS HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, today announced...
View ArticleClik here to view.
拓臻生物宣布其非酒精性脂肪性肝炎(NASH)候选药物TERN-101获得美国FDA快速通道认证
美国加州福斯特城与中国上海 (美国商业资讯)–Terns Pharmaceuticals 拓臻生物一家专注非酒精性脂肪性肝炎（NASH）和癌症创新疗法研发的全球生物制药公司，今天宣布其候选药物法尼醇X受体（FXR）激动剂TERN-101已获得美国食品和药物管理局（FDA）针对治疗NASH适应症的快速通道认证。 拓臻生物首席医学官Erin...
View ArticleClik here to view.
Terns Pharmaceuticals Receives Fast Track Designation From the FDA for...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014...
WALTHAM, Mass. Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the presentation of...
View ArticleClik here to view.
Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Chugai Pharma Taiwan Ltd., a wholly owned subsidiary of Chugai, obtained approval from the Taiwan Food and Drug Administration...
View ArticleClik here to view.
Terns Pharmaceuticals、NASH治療を目的とするFXR作動薬TERN-101に対するファストトラック指定をFDAより取得
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Taipei Exchange Reported by Scientific American as a Key Pillar in Taiwan...
TAIPEI, Taiwan Scientific American (November 2019 issue) has published Taiwan Healthcare & Life Sciences Review, a country-focused report presenting a comprehensive insight on biotech ecosystem...
View ArticleAVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia. View the full release here:...
View ArticleClik here to view.
武田薬品：2019年度第2四半期の堅調な連結業績と通期業績予想の上方修正について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502) (NYSE:TAK)： 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20191030006223/ja/ 2019年度上期の実質的な売上収益は対前年同期△0.2％（Pro-forma2）...
View ArticleClik here to view.
プロメセラ：日本における事業展開について
モン=サン=ギベール（ベルギー） & 東京 （ビジネスワイヤ） — 細胞由来の治療薬および肝臓病の分野で国際的なイノベーター企業であるPromethera Biosciences SA（以下、『プロメセラ』または『当社』）...
View ArticleClik here to view.
Promethera Biosciences: Announcement Regarding Business Activities in Japan
MONT-SAINT-GUIBERT, Belgium & TOKYO Promethera Biosciences SA (Group), a global innovator in cell-based medicines and liver diseases, announced the foundation of a new branch office in Tokyo,...
View ArticleClik here to view.
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug...
NASHVILLE, Tenn. & TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today...
View ArticleClik here to view.
Urovant Sciences Secures Substantial Financial Commitment, Commercial...
IRVINE, Calif. & BASEL, Switzerland Urovant Sciences (Nasdaq: UROV) today announced that its majority shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a...
View ArticleClik here to view.
Meitheal Pharmaceuticals Announces Completion of Majority Stake Investment...
CHICAGO Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, Illinois today announced the completion of a previously announced majority stake...
View Article